Training activity information
Details
Interpret and report on a range of genetic testing in haematological malignancies, to include:
- AML
- ALL
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the key genetic findings in AML and ALL and their clinical significance for diagnosis, prognosis, and treatment?
- What are the established guidelines and best practices for interpreting and reporting these types of genetic results, including nomenclature and classification of variants?
- What are the different components typically included in a genetic report for haematological malignancies, and what level of detail is required for different audiences (e.g., clinicians, MDT)?
- How will you develop your skills in translating raw genetic findings into clinically meaningful interpretations?
- Will you review example genetic reports for AML and ALL with your training officer or a senior colleague?
- What resources (e.g., relevant literature, classification guidelines, reporting templates) will you consult to prepare for interpretation and reporting?
- What potential challenges might you anticipate in interpreting and reporting (e.g., variants of uncertain significance, complex karyotypes)? How might you approach these?
In action
- How are you currently approaching the interpretation and synthesis of multi-modal data (e.g., cytogenetics, FISH, sequencing), and what real-time decisions are you making to focus on findings critical for diagnosis, prognosis, and treatment stratification?
- What challenges are you encountering in communicating complex data—such as variants of uncertain significance (VUS) or discordant results—and how are you ensuring your report remains clear, concise, and clinically actionable for haematologists?
- How are you ensuring your interpretation aligns with reporting guidelines, and what specialist advice or multidisciplinary input are you seeking right now to resolve ambiguity and ensure accuracy regarding methodologies and testing limitations?
On action
- What were the key genetic findings that you included in your reports?
- How did you structure your reports to ensure clarity and clinical relevance?
- Were there any challenges in interpreting the clinical significance of certain genetic findings?
- Did you improve your ability to interpret complex genetic data in the context of AML and ALL?
- Did you learn about the essential components of a comprehensive genetic report for haematological malignancies?
- How do you communicate the implications of genetic findings to clinicians effectively?
- What resources or guidelines will you use to inform your interpretation and reporting of genetic data?
- How will you ensure that your reports are timely, accurate, and clinically actionable?
- What feedback mechanisms can you use to improve your reporting skills
Beyond action
- Having gained more experience in interpreting and reporting on genetic findings in AML and ALL, how has your confidence and accuracy in generating clinical reports improved?
- Have you received feedback on your reports that has led to changes in your reporting style or the level of detail you include?
- How have the principles of result interpretation and reporting learned here been applied to other areas of cancer genomics you now work in?
- As our understanding of the prognostic and therapeutic significance of genetic markers in haematological malignancies evolves, how will your foundational reporting skills help you to communicate this information effectively in the future?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 3 |
Outcome
Analyse, interpret and report tests for patients referred with sporadic cancer. |